Suppr超能文献

坦桑尼亚耐多药结核病患者在治疗初期血浆药物活性的改善。

Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.

作者信息

Ndusilo Norah D, Heysell Scott K, Mpagama Stellah G, Gratz Jean, Segesela Farida H, Pazia Saumu J, Wang Xin-Qun, Houpt Eric R, Kibiki Gibson S

机构信息

Kilimanjaro Clinical Research Institute, Moshi, Tanzania.

Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, United States of America; Kibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.

出版信息

PLoS One. 2015 Mar 27;10(3):e0122769. doi: 10.1371/journal.pone.0122769. eCollection 2015.

Abstract

BACKGROUND

Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval.

METHODS

Plasma drug activity, as measured by the TB Drug Activity (TDA) assay at 2 and 4 weeks of treatment with a standardized MDR-TB regimen was performed in patients with pulmonary MDR-TB from Tanzania. TDA values were correlated with measures of early treatment outcome including every two week collection of sputum for time-to-positivity (TTP) in liquid culture from the MGIT 960 automated system. Patients were evaluated at 24 weeks and those surviving without delayed sputum culture conversion (>8 weeks), culture reversion after previously negative, or weight loss were defined as having a favorable outcome.

RESULTS

Twenty-five patients were enrolled with a mean age of 37 ±12 years. All were culture positive from the pretreatment sputum sample with a mean TTP in MGIT of 257 ±134 hours, and the median time to culture conversion on treatment was 6 weeks. Twenty patients (80%) had an increase in TDA, with the overall mean TDA at 2 weeks of 2.1 ±0.7 compared to 2.4 ±0.8 at 4 weeks (p = 0.005). At 2 weeks 13 subjects (52%) had a TDA value > 2-log killing against their own M. tuberculosis isolate compared to 17 subjects (68%) at 4 weeks (McNemar's exact test p = 0.29). An interim treatment outcome was able to be determined in 23 patients (92%), of whom 7 had a poor outcome (30%). An increase in TDA from week 2 to week 4 was associated with favorable outcome, [unadjusted OR = 20.0, 95% CI: 1.61-247.98, exact p = 0.017 and adjusted OR = 19.33, 95% CI: 1.55-241.5, exact p = 0.023].

CONCLUSIONS

The majority of patients with MDR-TB in Tanzania had an increase in plasma drug activity from week 2 to week 4 of treatment as measured by the TDA assay. Understanding the etiology and full impact of this dynamic may inform therapeutic intervention.

摘要

背景

在耐多药结核病(MDR-TB)治疗患者中,个体药代动力学变异性可能很常见,但资源有限环境及整个治疗早期阶段的数据较少。

方法

对来自坦桑尼亚的肺结核MDR-TB患者,采用标准化MDR-TB治疗方案治疗2周和4周时,通过结核药物活性(TDA)测定法测量血浆药物活性。TDA值与早期治疗结果指标相关,包括每两周收集痰液,以检测MGIT 960自动化系统液体培养中的痰转阴时间(TTP)。在24周时对患者进行评估,那些存活且无延迟痰培养转阴(>8周)、先前阴性后培养复阳或体重减轻的患者被定义为治疗结果良好。

结果

纳入25例患者,平均年龄37±12岁。所有患者治疗前痰样本培养均为阳性,MGIT中平均TTP为257±134小时,治疗中痰培养转阴的中位时间为6周。20例患者(80%)TDA升高,治疗2周时总体平均TDA为2.1±0.7,4周时为2.4±0.8(p = 0.005)。治疗2周时,13例受试者(52%)的TDA值对其自身结核分枝杆菌分离株的杀菌对数>2,4周时为17例受试者(68%)(McNemar确切概率检验p = 0.29)。23例患者(92%)能够确定中期治疗结果,其中7例治疗结果不佳(30%)。TDA从第2周增加到第4周与良好的治疗结果相关,[未调整的OR = 20.0,95%CI:1.61 - 247.98,确切p = 0.017;调整后的OR = 19.33,95%CI:1.55 - 241.5,确切p = 0.023]。

结论

坦桑尼亚大多数MDR-TB患者在治疗第2周和第4周时,通过TDA测定法测量的血浆药物活性有所增加。了解这种动态变化的病因和全面影响可能为治疗干预提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb56/4376785/44d99ea7005c/pone.0122769.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验